Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
5.43
+0.07 (1.31%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Atea Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Atea Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $9.42. The average 1-year stock price forecast is 73.48% higher than the current stock price, while the lowest is $7.00 (+28.91%) and the highest is $11.25 (+107.18%).
Price Target: $9.42 (+73.48%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Atea Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Mar '26 | Apr '26 | May '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Reiterates $6 → $7 | Hold | Reiterates | $6 → $7 | +28.91% | Aug 13, 2026 |
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Aug 12, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $6 → $10 | Buy | Maintains | $6 → $10 | +84.16% | Mar 9, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
60.00M
EPS This Year
-1.99
from -1.94
EPS Next Year
-1.48
from -1.99
EPS and Forward PE are based on non-GAAP adjusted numbers.